vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and WATTS WATER TECHNOLOGIES INC (WTS). Click either name above to swap in a different company.
WATTS WATER TECHNOLOGIES INC is the larger business by last-quarter revenue ($677.3M vs $339.0M, roughly 2.0× HAEMONETICS CORP). WATTS WATER TECHNOLOGIES INC runs the higher net margin — 14.7% vs 13.2%, a 1.5% gap on every dollar of revenue. On growth, WATTS WATER TECHNOLOGIES INC posted the faster year-over-year revenue change (21.4% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $6.6M). Over the past eight quarters, WATTS WATER TECHNOLOGIES INC's revenue compounded faster (6.5% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
AERCO International, Inc. is a manufacturer and supplier of commercial condensing boilers, high efficiency water heating equipment and energy recovery systems in the HVAC/plumbing industry across a variety of markets including education, lodging, government, office buildings, healthcare, industrial and multifamily housing. In 1949, AERCO introduced the industry's first semi-instantaneous, tankless steam-to-water water heater. In 1988, AERCO introduced the first condensing and fully modulating...
HAE vs WTS — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $677.3M |
| Net Profit | $44.7M | $99.6M |
| Gross Margin | 59.7% | 48.1% |
| Operating Margin | 19.9% | 19.6% |
| Net Margin | 13.2% | 14.7% |
| Revenue YoY | -2.7% | 21.4% |
| Net Profit YoY | 19.3% | 34.6% |
| EPS (diluted) | $0.95 | $2.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $677.3M | ||
| Q4 25 | $339.0M | $625.1M | ||
| Q3 25 | $327.3M | $611.7M | ||
| Q2 25 | $321.4M | $643.7M | ||
| Q1 25 | $330.6M | $558.0M | ||
| Q4 24 | $348.5M | $540.4M | ||
| Q3 24 | $345.5M | $543.6M | ||
| Q2 24 | $336.2M | $597.3M |
| Q1 26 | — | $99.6M | ||
| Q4 25 | $44.7M | $83.7M | ||
| Q3 25 | $38.7M | $82.2M | ||
| Q2 25 | $34.0M | $100.9M | ||
| Q1 25 | $58.0M | $74.0M | ||
| Q4 24 | $37.5M | $67.5M | ||
| Q3 24 | $33.8M | $69.1M | ||
| Q2 24 | $38.4M | $82.0M |
| Q1 26 | — | 48.1% | ||
| Q4 25 | 59.7% | 49.5% | ||
| Q3 25 | 59.5% | 48.8% | ||
| Q2 25 | 59.8% | 50.6% | ||
| Q1 25 | 58.4% | 48.8% | ||
| Q4 24 | 55.5% | 46.7% | ||
| Q3 24 | 54.2% | 47.3% | ||
| Q2 24 | 52.0% | 47.7% |
| Q1 26 | — | 19.6% | ||
| Q4 25 | 19.9% | 18.2% | ||
| Q3 25 | 17.9% | 18.2% | ||
| Q2 25 | 16.8% | 21.0% | ||
| Q1 25 | 21.6% | 15.7% | ||
| Q4 24 | 16.9% | 16.5% | ||
| Q3 24 | 15.0% | 17.1% | ||
| Q2 24 | 11.8% | 18.7% |
| Q1 26 | — | 14.7% | ||
| Q4 25 | 13.2% | 13.4% | ||
| Q3 25 | 11.8% | 13.4% | ||
| Q2 25 | 10.6% | 15.7% | ||
| Q1 25 | 17.5% | 13.3% | ||
| Q4 24 | 10.8% | 12.5% | ||
| Q3 24 | 9.8% | 12.7% | ||
| Q2 24 | 11.4% | 13.7% |
| Q1 26 | — | $2.97 | ||
| Q4 25 | $0.95 | $2.50 | ||
| Q3 25 | $0.81 | $2.45 | ||
| Q2 25 | $0.70 | $3.01 | ||
| Q1 25 | $1.17 | $2.21 | ||
| Q4 24 | $0.74 | $2.02 | ||
| Q3 24 | $0.66 | $2.06 | ||
| Q2 24 | $0.74 | $2.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $374.7M |
| Total DebtLower is stronger | $1.2B | $197.8M |
| Stockholders' EquityBook value | $911.5M | $2.1B |
| Total Assets | $2.5B | $2.9B |
| Debt / EquityLower = less leverage | 1.34× | 0.09× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $374.7M | ||
| Q4 25 | $363.4M | $405.5M | ||
| Q3 25 | $296.4M | $457.7M | ||
| Q2 25 | $292.9M | $369.3M | ||
| Q1 25 | $306.8M | $336.8M | ||
| Q4 24 | $320.8M | $386.9M | ||
| Q3 24 | $299.3M | $303.9M | ||
| Q2 24 | $344.4M | $279.4M |
| Q1 26 | — | $197.8M | ||
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $911.5M | $2.0B | ||
| Q3 25 | $849.2M | $2.0B | ||
| Q2 25 | $882.3M | $1.9B | ||
| Q1 25 | $820.8M | $1.8B | ||
| Q4 24 | $906.9M | $1.7B | ||
| Q3 24 | $878.9M | $1.7B | ||
| Q2 24 | $905.4M | $1.6B |
| Q1 26 | — | $2.9B | ||
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | $2.4B | $2.7B | ||
| Q2 25 | $2.5B | $2.6B | ||
| Q1 25 | $2.5B | $2.5B | ||
| Q4 24 | $2.5B | $2.4B | ||
| Q3 24 | $2.5B | $2.4B | ||
| Q2 24 | $2.5B | $2.4B |
| Q1 26 | — | 0.09× | ||
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $17.9M |
| Free Cash FlowOCF − Capex | $87.2M | $6.6M |
| FCF MarginFCF / Revenue | 25.7% | 1.0% |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 2.09× | 0.18× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $317.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $17.9M | ||
| Q4 25 | $93.6M | $154.7M | ||
| Q3 25 | $111.3M | $122.4M | ||
| Q2 25 | $17.4M | $69.7M | ||
| Q1 25 | $116.6M | $55.2M | ||
| Q4 24 | $43.8M | $139.5M | ||
| Q3 24 | $48.8M | $90.7M | ||
| Q2 24 | $-27.4M | $85.3M |
| Q1 26 | — | $6.6M | ||
| Q4 25 | $87.2M | $140.3M | ||
| Q3 25 | $106.3M | $110.9M | ||
| Q2 25 | $13.6M | $59.5M | ||
| Q1 25 | $100.9M | $45.6M | ||
| Q4 24 | $35.2M | $127.5M | ||
| Q3 24 | $39.4M | $84.3M | ||
| Q2 24 | $-33.1M | $78.5M |
| Q1 26 | — | 1.0% | ||
| Q4 25 | 25.7% | 22.4% | ||
| Q3 25 | 32.5% | 18.1% | ||
| Q2 25 | 4.2% | 9.2% | ||
| Q1 25 | 30.5% | 8.2% | ||
| Q4 24 | 10.1% | 23.6% | ||
| Q3 24 | 11.4% | 15.5% | ||
| Q2 24 | -9.8% | 13.1% |
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 2.3% | ||
| Q3 25 | 1.5% | 1.9% | ||
| Q2 25 | 1.2% | 1.6% | ||
| Q1 25 | 4.7% | 1.7% | ||
| Q4 24 | 2.5% | 2.2% | ||
| Q3 24 | 2.7% | 1.2% | ||
| Q2 24 | 1.7% | 1.1% |
| Q1 26 | — | 0.18× | ||
| Q4 25 | 2.09× | 1.85× | ||
| Q3 25 | 2.88× | 1.49× | ||
| Q2 25 | 0.51× | 0.69× | ||
| Q1 25 | 2.01× | 0.75× | ||
| Q4 24 | 1.17× | 2.07× | ||
| Q3 24 | 1.44× | 1.31× | ||
| Q2 24 | -0.71× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
WTS
| segment net | $517.8M | 76% |
| Other | $159.5M | 24% |
